Abvc Biopharma vs Medicinova
Medicinova is the larger business, with $409,657 of revenue in fiscal 2025 against $296,000 for Abvc Biopharma (1.4 times as much). Abvc Biopharma grew faster (-41.9% against -59.0%). Abvc Biopharma kept more of each dollar of sales as profit: a net margin of -2671.8% against -2928.8%. Medicinova carries less debt relative to equity (0.0% against 6.8%).
| Latest fiscal year | Abvc BiopharmaABVC, 2025 | MedicinovaMNOV, 2025 |
|---|---|---|
| Revenue | $296,000 | $409,657 |
| Revenue growth | -41.9% | -59.0% |
| Net income | −$7.9m | −$12.0m |
| Operating margin | -2416.0% | -3242.5% |
| Net margin | -2671.8% | -2928.8% |
| Return on equity | -128.2% | -23.1% |
| Free cash flow | −$3.0m | −$9.8m |
| Cash | $681,480 | $30.8m |
| Total debt | $755,512 | $0 |
| Debt to equity | 6.8% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 19 | — |
| Market value | $25.6m | $70.9m |
| Price vs our value range | — | — |
| Moat score | 23 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 1 sales |